Literature DB >> 32164085

[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

.   

Abstract

At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.

Entities:  

Keywords:  Chloroquine; Novel coronavirus pneumonia

Mesh:

Substances:

Year:  2020        PMID: 32164085     DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  84 in total

1.  Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.

Authors:  Ahmed Awad Adeel
Journal:  Sudan J Paediatr       Date:  2020

Review 2.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

3.  Concentration-dependent mortality of chloroquine in overdose.

Authors:  James A Watson; Joel Tarning; Richard M Hoglund; Frederic J Baud; Bruno Megarbane; Jean-Luc Clemessy; Nicholas J White
Journal:  Elife       Date:  2020-07-08       Impact factor: 8.140

Review 4.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

5.  Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.

Authors:  Meghan E Sise; Meridale V Baggett; Jo-Anne O Shepard; Jacob S Stevens; Eugene P Rhee
Journal:  N Engl J Med       Date:  2020-05-13       Impact factor: 91.245

Review 6.  Coronavirus Disease 2019-COVID-19.

Authors:  Kuldeep Dhama; Sharun Khan; Ruchi Tiwari; Shubhankar Sircar; Sudipta Bhat; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Clin Microbiol Rev       Date:  2020-06-24       Impact factor: 26.132

7.  Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.

Authors:  João João Mendes; José Artur Paiva; Filipe Gonzalez; Paulo Mergulhão; Filipe Froes; Roberto Roncon; João Gouveia
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24

Review 8. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

9.  Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.

Authors:  Srinivasa Reddy Bonam; Sylviane Muller; Jagadeesh Bayry; Daniel J Klionsky
Journal:  Autophagy       Date:  2020-06-24       Impact factor: 16.016

10.  Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin.

Authors:  Olajumoke A Olateju; Chinedum P Babalola; Olujide O Olubiyi; Olayinka A Kotila; David A Kwasi; Anderson O Oaikhena; Iruka N Okeke
Journal:  Front Microbiol       Date:  2021-06-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.